SQ sublingual immunotherapy tablets for children with allergic rhinitis: A review of phase three trials

Abstract

AbstractAimTo provide paediatricians with a summary of efficacy and safety of SQ sublingual immunotherapy (SLIT) tablets from phase three, randomised, double‐blind, placebo‐controlled trials in children and adolescents with allergic rhinitis or rhinoconjunctivitis, with and without asthma.MethodsPubMed searches were conducted and unpublished data were included if necessary.ResultsOf the 93 publications, 12 were identified reporting 10 trials. One trial was excluded as paediatric‐specific efficacy data were unavailable. The nine eligible trials evaluated grass, house dust mite, ragweed and tree SLIT tablets. Consistent reductions in allergic rhinitis or rhinoconjunctivitis symptoms and medication use were observed with SQ SLIT tablets versus placebo. In a five‐year trial, sustained reduction of allergic rhinoconjunctivitis symptoms, asthma symptoms and medication use were observed with SQ grass SLIT tablet versus placebo. The number‐needed‐to‐treat to prevent asthma symptoms and medication use in one additional child during follow‐up was lowest in younger children. SQ SLIT tablets were generally well tolerated across trials.ConclusionEvidence supports use of SQ SLIT tablets in children and adolescents with allergic rhinitis or rhinoconjunctivitis, with and without asthma. Long‐term data demonstrate disease‐modifying effects of SQ grass SLIT tablet and suggest the clinical relevance of initiating allergy immunotherapy earlier in the disease course.